744-P: LIVE India: A Post-hoc Subanalysis of FINE-ASIA and GOAL Registries to Measure Effectiveness and Safety of Glargine 100 U/mL (Gla-100) in Insulin-Naïve Indian Adults with T2DM

Abstract

Real-world data on the effectiveness and safety of Gla-100 is limited in Indian people with T2DM. In a post-hoc analysis the effectiveness and hypoglycemia risk was studied in Indian T2DM participants (N=955) who started Gla-100 under daily routine practice and were followed-up for 6 months in the observational FINE-ASIA (overall N=2679) and GOAL (overall N=2704) registries. Mean age and duration of diabetes were 54.7±9.8 years and 9.8±6.3 years, respectively. HbA1c, FPG, body weight, dose, and incidence of hypoglycemia outcomes are summarized in Table. Mean HbA1c and FPG were significantly reduced after 6 months of Gla-100 treatment (-2.07±1.42%; -94.4±65.2 mg/dL). HbA1c targets of <7.0% and <7.5% were achieved in 292 (30.6%) and 589 (61.7%) of participants, respectively. Overall incidence of hypoglycemia was low (n=52; 5.4%); only 2 participants (0.2%) reported severe hypoglycemia. Insulin titration was suboptimal with mean increments of 2.5 U/day after 6 months. This post hoc analysis in Indian T2DM people initiating Gla-100 demonstrates significant improvements in glycemic parameters but reveals delay in insulin initiation and only a small proportion attain target HbA1c in real-world setting, and dose titration was sub-optimal despite the low incidence of hypoglycemia.View largeDownload slideView largeDownload slide DisclosureV. C. Deshmukh: None. S. Mohanasundaram: Employee; Self; Sanofi. C. Trivedi: None. V. Salvi: Employee; Self; Sanofi. P. R. Narvekar: None. S. Kale: None. S. Ramakrishnan: None. G. Goyal: Advisory Panel; Self; Sanofi. T. Chaudhury: None. M. Chadha: Advisory Panel; Self; Sanofi, Speaker’s Bureau; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., Novo Nordisk Pharma Ltd. M. S. Chawla: Speaker’s Bureau; Self; Abbott Diabetes, Boehringer Ingelheim Pharmaceuticals, Inc., Colgate-Palmolive, Eli Lilly and Company, Glenmark Pharmaceuticals Limited, Novo Nordisk. S. Mukherjee: None. S. U. Pitale: Speaker’s Bureau; Self; Sanofi. D. Basu: None. R. Ghosh: Employee; Self; Sanofi. A. Nair: Employee; Self; Sanofi.FundingSanofi India